Navigation Links
Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial

SYDNEY, Australia, April 26, 2007 /PRNewswire-FirstCall/ -- Australian drug development company Alchemia Limited today announced preliminary results from its randomised Phase II clinical trial in patients with metastatic colorectal cancer, where Alchemia's drug HyCAMP(TM) was compared to irinotecan which is considered to be a cornerstone drug for the treatment of colorectal cancer. This announcement is being made at a preliminary stage of the analysis in accordance with the ASX disclosure requirements once the company became aware of the results reported below.

Primary safety endpoint - Comparison of the incidence of late grade 3 or 4 diarrhoea in patients receiving HyCAMP(TM) versus irinotecan alone:

    -- not met due to lower than expected incidence of diarrhoea in the

       control arm


    Secondary safety endpoints:


    -- No major differences in overall adverse events between the two

       treatment arms


    Secondary efficacy endpoints:


    -- 38 of 41 (93%) HyCAMP(TM) patients compared to 28 of 35 (80%)

       irinotecan patients completed 2 cycles (p=0.099)


    -- 14 of 41 (34%) HyCAMP(TM) patients compared to 5 of 35 (14%) irinotecan

       patients completed the full 8 cycles (p=0.064)


    -- Patients on HyCAMP(TM) received a median of 6 cycles of therapy,

       compared to 2 for irinotecan alone (p=0.005)


    -- Median progression free survival for HyCAMP(TM) patients was 5.2

       months, compared to 2.4 months for the irinotecan arm (p=0.014).

The Phase II trial commenced in December 2004 and patient accrual closed on 30 June 2006. In the randomised trial, 80 patients with metastatic colorectal cancer who had previously failed treatment with the anti-cancer drug 5-fluoro uracil were eligible to receive up to eight cycles of chemotherapy in the form of irinotecan or HyCAMP(TM) intravenously. The primary endpoint of the trial was safety (incidence
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:7/14/2014)... , July 14, 2014 ... a technology partnership with global bioengineering leader ... technology for quick-to-market products. The ... DNA2.0,s machine learning optimization technologies, such as ... the process of engineering proteins in the ...
(Date:7/14/2014)... , July 14, 2014 Sinovac Biotech Ltd. (NASDAQ: ... , announced today that it will hold its 2014 Annual Meeting ... The meeting will be held at No. 39 Shangdi Xi Road, Haidian ... of July 9, 2014 will be eligible to vote and are invited ... approve the re-election of Weidong Yin , Yuk Lam Lo ...
(Date:7/14/2014)... 14, 2014  Mylan Inc. (NASDAQ: MYL ) ... with Abbott (NYSE: ABT ... non-U.S. developed markets specialty and branded generics business ("the Assets") ... will receive 105 million shares of the combined company ... $50.20 on Friday, July 11, 2014, representing an approximately 21% ...
Breaking Medicine Technology:Pareto Biotechnologies Announces Technology Partnership With DNA2.0, Inc. 2Pareto Biotechnologies Announces Technology Partnership With DNA2.0, Inc. 3Sinovac Schedules 2014 Annual Meeting of Shareholders 2Sinovac Schedules 2014 Annual Meeting of Shareholders 3Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 2Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 3Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 4Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 5Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 6Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 7Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 8Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 9Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 10Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 11
... Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) management ... Tuesday, October 25th at 11:30 a.m. Pacific/ 2:30 p.m. Eastern/ ... the Palace Hotel in San Francisco. The ... for replay after the presentation. The webcast can be accessed ...
... Colo., Oct. 18, 2011 SomaLogic, Inc., announced today ... with Novartis to use its unique proprietary proteomics technology ... "We are excited by this opportunity to ... robust biomarkers, validate novel drug targets, and even develop ...
Cached Medicine Technology:SomaLogic Announces Research Agreement with Leading Global Pharmaceutical Company to Accelerate Pharmaceutical Discovery and Development 2
(Date:7/14/2014)... Wa (PRWEB) July 14, 2014 Dry eyes, ... of aging anymore. As recent research have pointed out, today’s ... from dry eyes as a result of using laptops ... or daily lives. , Because of this phenomenon, it has ... that will not just cure them from having dry eyes, ...
(Date:7/14/2014)... Cabin Chiang Mai, Asia’s leading inpatient addiction treatment centre, ... – a free comprehensive aftercare service for clients who ... they live in the world. , The Cabin firmly ... maintain their recovery after successfully completing primary treatment should ... As a chronic disease, addicts in recovery are always ...
(Date:7/14/2014)... 14, 2014 EurekaMag.com has newly published ... is a contagious liver disease that ranges in ... to a serious, lifelong illness that attacks the liver. ... have chronic Hepatitis C virus infection of which approximately ... research category covers all studies on Hepatitis C ...
(Date:7/14/2014)... According to the Boost Your Bust book review recently ... want to learn how to increase the size of their breasts ... chapters including:, , Chapter 1 – What Are ... 2 – How Natural Breast Enlargement Works , Chapter ... Chapter 4 – The Groundwork , Chapter ...
(Date:7/14/2014)... Vaginal Mesh lawsuit claims continue to ... mesh manufacturers in the U.S. District Court, Southern District ... federal complaints are pending against pelvic mesh manufacturers that ... (MDL No. 2325), and C.R. Bard, Inc., (MDL No. ... Mesh lawsuit claims pending, according to statistics from the ...
Breaking Medicine News(10 mins):Health News:Dry Eye Handbook Review | Taking Care of One’s Vision by Using Natural Methods – Vinamy.com 2Health News:Dry Eye Handbook Review | Taking Care of One’s Vision by Using Natural Methods – Vinamy.com 3Health News:The Cabin Chiang Mai Addiction Rehab Launches Industry-leading Aftercare Service 2Health News:The Cabin Chiang Mai Addiction Rehab Launches Industry-leading Aftercare Service 3Health News:EurekaMag.com Publishes 64,900 New Studies on Hepatitis C 2Health News:Boost Your Bust Book Review Exposes Jenny Bolton's Breast Enhancement Guide – Vkool.com 2Health News:Boost Your Bust Book Review Exposes Jenny Bolton's Breast Enhancement Guide – Vkool.com 3Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 2Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 3Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 4Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 5
... Lube Leader Reaches Halfway Point in Campaign to Support American ... Heart Association,s Go Red For Women(TM) Movement, HOUSTON, Feb. ... to its goal of raising $1 million for the,American Heart ... Heart Month are almost in the rear-view mirror, Jiffy,Lube wants ...
... according to a study of more than 77,000 vitamin ... risk of developing it. , Our study of supplemental ... show any evidence for a decreased risk of lung ... of the University of Washington, in Seattle. Indeed, increasing ...
... and a decision algorithm, rather than standard hospital protocols, ... patients with severe sepsis or septic shock can reduce ... costs all without adverse effects on patients, according to ... possible to customize antibiotic treatment duration in patients with ...
... UT Southwestern Medical Center have determined that the level, or ... children with sickle cell anemia who are at an increased ... have also found that a published method used to predict ... , Stroke is a serious but increasingly preventable complication of ...
... affected by ... rare diseases, NEW YORK, Feb. ... Day will be launched on Friday 29,February...because it,s a rare day that ... Shire plc at:, http://media.medialink.com/WebNR.aspx?story=34701 ), Collectively, rare diseases aren,t ...
... to Reliance on Spill-Proof,Cups, GLENDALE, Calif., Feb. 28 ... Dental Hygienists, Association,(CDHA) today urged parents and caregivers to ... "We all know that sippy cups are a godsend ... "But they need to be used wisely and,properly in ...
Cached Medicine News:Health News:Jiffy Lube(R) Continues Drive Against Heart Disease with Maintenance Partners for Life Campaign 2Health News:Jiffy Lube(R) Continues Drive Against Heart Disease with Maintenance Partners for Life Campaign 3Health News:Jiffy Lube(R) Continues Drive Against Heart Disease with Maintenance Partners for Life Campaign 4Health News:Certain vitamin supplements may increase lung cancer risk, especially in smokers 2Health News:Customized treatments for sepsis lower treatment time and reduce length of ICU stays 2Health News:UT Southwestern researchers investigate predictors for sickle-cell-anemia complications 2Health News:VIDEO from Medialink and Shire plc: Rare Diseases Must Be Top of the Health Agenda 2Health News:VIDEO from Medialink and Shire plc: Rare Diseases Must Be Top of the Health Agenda 3Health News:California Dental Hygienists Offer Tips for Safe Sippy Cup Use 2
High resolution, multi-frequency, HST version of the UST-987-7.5. Provides even greater image detail, better resolution, and penetration....
... Penetration Steered Linear Peripheral Vascular transducer, with ... MHz. It is our newest vascular ... 4 different settings to optimize imaging of ... color and Doppler sensitivity of this transducer ...
... Super High Density, multi-frequency, linear ... "twist on the UST-5536, this ... it sweeps horizontally as well ... axis so that target lesions ...
... The UST-MC11-8731 is a perfect alternative ... are used to seeing more of a ... of the transducer in the hand., This ... shaped convex intraoperative transducer. The UST-MC11-8731 nestles ...
Medicine Products: